Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Diffuse large B-cell lymphoma, drawn from the whole corpus: 138 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Primary refractory disease.
Also on OnCo: Resistance atlas · Lines of therapy.
CAR-T access and cost.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Primary refractory disease (~10-15%) still has poor outcomes even with CAR-T; CD19-negative and CD20-negative escape after targeted therapy.
Also on OnCo: Resistance atlas · Lines of therapy.
No head-to-head comparison of bispecifics and CAR-T; sequencing is by access rather than evidence.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Overall survival is hard to demonstrate for bispecifics against chemotherapy with crossover and effective later lines (EPCORE DLBCL-1).
Trial generalisability: STARGLO's rejection shows regional enrolment can decide approvals.
CNS relapse: prophylaxis with high-dose methotrexate is of uncertain benefit and CNS-penetrant options are few.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Older and frail patients are underrepresented; R-mini-CHOP cure rates lag and cellular therapies carry toxicity.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Cost and access: CAR-T requires certified centres; bispecific CRS management needs infrastructure; lenalidomide-based triplets add expense.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Response-adapted therapy: interim PET is unreliable and ctDNA is not yet a regulatory endpoint.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 71 changes by month →When this page itself was last checked or edited.
sBLA for frontline high-risk DLBCL (frontMIND) planned H1 2026
EPCORE DLBCL-1 topline: PFS met, OS (US primary endpoint) not met
R-CHOP × 6 (or Pola-R-CHP); consider 4 cycles plus 2 rituximab in young low-risk patients (FLYER). (NCCN Category 1)
Pola-R-CHP × 6 (POLARIX) or R-CHOP × 6; tafasitamab + lenalidomide + R-CHOP (frontMIND) pending approval for IPI 3-5; DA-EPOCH-R for double-hit lymphoma; CNS prophylaxis for high CNS-IPI (contested). (NCCN Pola-R-CHP category 1 for IPI 2-5)
CD19 CAR-T (axi-cel or liso-cel) preferred over salvage chemotherapy and transplant (ZUMA-7, TRANSFORM); bridging therapy while manufacturing; bispecific ± chemotherapy if CAR-T unavailable. (NCCN Category 1 (axi-cel, liso-cel))